1-7 of 7
Anthony W Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef
Journal: Blood
Blood (2024) 144 (Supplement 1): 7614.
https://doi.org/10.1182/blood-2024-207898
Published: 2024
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Kim Linton, John N. Allan, Andrew S Park, Anthony W Wang, Summer Tran, Alex Mutebi, Zhijie Ding, Quan Chen, Tycel J. Phillips
Journal: Blood
Blood (2024) 144 (Supplement 1): 1703.
https://doi.org/10.1182/blood-2024-200989
Published: 2024
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Karen Cumings, Viktor Chirikov, Zhijie Ding, Felipe Marques Goncalves, Nicole Heaps, Savreet Bains Chawla, Anthony W Wang, Mohammad Atiya, Fernando Rivas Navarro, Elena Favaro, Daniela Hoehn, Alex Mutebi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7802.
https://doi.org/10.1182/blood-2024-200799
Published: 2024
Journal Articles

A Canadian Cost-Utility Analysis of Epcoritamab Versus Current Therapies in Third-Line or Later Large B-Cell Lymphoma

Shivani Kamdar, David Macdonald, Athina Palaka, Angelina Addae, Colin Vicente, Anthony W Wang, Dipti Tankala, Stephane Barakat
Journal: Blood
Blood (2024) 144 (Supplement 1): 7617.
https://doi.org/10.1182/blood-2024-210199
Published: 2024
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Javier Munoz, Allison C. Rosenthal, Andrew Ip, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7760.
https://doi.org/10.1182/blood-2024-203876
Published: 2024
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Andrew Ip, Javier Munoz, Allison C. Rosenthal, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7757.
https://doi.org/10.1182/blood-2024-203540
Published: 2024